Last quote by John Rountree
I think they've got a viable strategy. They're continuing to innovate and they're investing a lot in R&D...the biosimilar (an almost identical biologic copy of an original drug) is a threat to them and they've just got to work harder. You're going to get trial setbacks but they've just got to keep ploughing ahead with that innovation.feedback
Sep 11 2017
This page is completely dedicated to what John Rountree has to say. All of John Rountree’s quotes are organized here by date and topic. The most recent quote attributed to John Rountree came from an article called Roche slumps on another drug setback as sales forecasts come into question: “This is another blow and people will start to question that ability of that part of the organization to deliver really quality development.”.
Take our quote verification challenge and find out !
Quotes by John Rountree
Sep 11 2017
This is another blow and people will start to question that ability of that part of the organization to deliver really quality development.feedback
Aug 26 2017
With supply chains across different countries, if there are extra barriers and paperwork clearly that will be a deterrent.feedback
Aug 06 2017
It all emphasises the importance the new GSK executive team puts on stability and long-term performance, rather than high-risk and high-reward R&D. It does not fit as well with a view that GSK will be a magnet for developing game-changing pharmaceutical R&D innovation. Investors that are more interested in high-upside with risk can take on this unit and give it more focus and space than is currently possible under GSK.feedback
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided